Omadacycline

Drug Profile

Omadacycline

Alternative Names: Amadacycline; BAY 73-6944; BAY 73-7388; MK-2764; Neopentyl aminomethylminocycline; PTK-0796; PTK796

Latest Information Update: 24 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Paratek Pharmaceuticals
  • Developer Merck & Co; Paratek Pharmaceuticals
  • Class Antibacterials; Small molecules; Tetracyclines
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Community-acquired pneumonia; Skin and soft tissue infections
  • Phase I Nosocomial infections; Urinary tract infections
  • Preclinical Acute sinusitis; Respiratory tract infections
  • Research Anthrax; Plague

Most Recent Events

  • 02 Aug 2017 Paratek Pharmaceuticals intends to initiate rolling submission in December 2017 based on pre-NDA meetings with the US FDA
  • 19 Jul 2017 Paratek Pharmaceuticals plans to initiate a proof-of-concept phase II trial for Pyelonephritis in December 2017
  • 19 Jul 2017 Efficacy and adverse events data from the phase III OASIS-2 trial in Skin and soft-tissue infections released by Paratek Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top